


# Clinical Pathway for Medical Management of Alcohol Withdrawal in WMS



## MONITORING PROTOCOL

Complete the initial assessment and then assess according to symptoms & scoring:

**Severe withdrawal**      **Monitor q1h**  
CIWA-Ar  $\geq 20$ , severe tremor, or profuse sweating

**Moderate withdrawal**      **Monitor q2h**  
CIWA-Ar 10-19, moderate tremor or sweating

**Mild withdrawal**      **Monitor q4h**  
CIWA-Ar 0-9, mild tremor  
BP, HR, T, RR, SpO<sub>2</sub> with each assessment

## TRANSFER TO EMERGENCY DEPARTMENT IF:

- Tremor not improving/worsening despite **80mg** diazepam (**8mg** lorazepam)
- Tachycardia (HR > 120bpm) or hypertension (elevation of systolic or diastolic BP 20-30mmHG above baseline)
- Repeated vomiting or profuse sweating
- Seizures, confusion, hallucinations, delusions, or agitation

## USE LORAZEPAM IF:

- Taking opioids/sedating medications
- Severe liver dysfunction (cirrhosis, severe hepatitis)
- Low serum albumin
- Respiratory failure or distress (severe asthma, COPD, pneumonia)
- Age 60+

## GABAPENTIN

Consider gabapentin in place of benzodiazepines when the client is taking opioids/sedating medications, has severe liver dysfunction, low serum albumin, respiratory failure or distress, or is 60+. Gabapentin is **not proven** to be effective against alcohol withdrawal seizures. Use this protocol only when low risk of seizures, DTs, or severe withdrawal.

### Gabapentin for acute withdrawal:

Days 1-3: **300mg** QID +/- **300-600mg** hs  
Day 4: **300mg** TID +/- **300mg** hs  
Day 5: **300mg** BID  
Day 6: **300mg** hs

When benzodiazepines are utilized, consider switching to gabapentin from day 3 on, as a benzodiazepine-sparing method, for management of post-acute withdrawal and as an anti-craving medication.

### Gabapentin for post-acute withdrawal:

Day 3: **300mg** hs  
Day 4: **300mg** BID  
Day 5: **300mg** TID  
Continue to titrate to effect, max recommended dose **1800mg/day**